Brokerages Set Haemonetics Corporation (NYSE:HAE) Price Target at $83.89

Shares of Haemonetics Corporation (NYSE:HAE) have been given an average recommendation of “Moderate Buy” by the eleven brokerages that are currently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $83.8889.

A number of brokerages have issued reports on HAE. BTIG Research reissued a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a research report on Friday, February 6th. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Mizuho dropped their price objective on Haemonetics from $90.00 to $80.00 and set an “outperform” rating for the company in a research note on Friday, February 6th. Needham & Company LLC downgraded Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, December 15th. Finally, Barrington Research set a $94.00 target price on Haemonetics in a research note on Friday, February 6th.

Haemonetics Price Performance

Shares of HAE opened at $58.58 on Monday. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32. The stock has a market cap of $2.72 billion, a PE ratio of 16.14, a P/E/G ratio of 1.23 and a beta of 0.28. The firm has a 50-day simple moving average of $64.33 and a two-hundred day simple moving average of $64.82. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, topping the consensus estimate of $1.27 by $0.04. The firm had revenue of $338.97 million for the quarter, compared to analyst estimates of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, analysts forecast that Haemonetics will post 4.55 EPS for the current year.

Institutional Trading of Haemonetics

Hedge funds have recently made changes to their positions in the business. Kemnay Advisory Services Inc. acquired a new position in shares of Haemonetics in the fourth quarter valued at approximately $26,000. True Wealth Design LLC lifted its holdings in Haemonetics by 6,700.0% during the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 335 shares in the last quarter. Leonteq Securities AG acquired a new stake in Haemonetics during the 4th quarter worth approximately $30,000. EverSource Wealth Advisors LLC boosted its position in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 396 shares during the period. Finally, Kestra Advisory Services LLC purchased a new position in Haemonetics in the 4th quarter valued at approximately $34,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.